# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
HC Wainwright & Co. analyst Andrew Fein maintains Zentalis Pharma (NASDAQ:ZNTL) with a Buy and lowers the price target f...
Stifel analyst Bradley Canino maintains Zentalis Pharma (NASDAQ:ZNTL) with a Buy and lowers the price target from $36 to $32.
Zentalis® Pharmaceuticals, Inc. (NASDAQ:ZNTL), a clinical-stage biopharmaceutical company discovering and developing clinically...
HC Wainwright & Co. analyst Andrew Fein reiterates Zentalis Pharma (NASDAQ:ZNTL) with a Buy and maintains $46 price target.
Wedbush analyst Robert Driscoll maintains Zentalis Pharma (NASDAQ:ZNTL) with a Neutral and raises the price target from $12 ...
Zentalis Pharma (NASDAQ:ZNTL) reported quarterly losses of $(4.47) per share. This is a 0.22 percent increase over losses of $(...